NANOMICRO(SH:688690)2023-04-25 16:00Financial Performance - The company's operating revenue for Q1 2023 was CNY 13,211.39 million, a decrease of 6.21% compared to the same period last year[4]. - Net profit attributable to shareholders was CNY 1,235.84 million, down 79.71% year-on-year[4]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 598.64 million, a decrease of 89.35% year-on-year[4]. - Basic earnings per share were CNY 0.0307, down 79.84% year-on-year[4]. - Total revenue for Q1 2023 was CNY 132,113,888.95, a decrease of 6.0% compared to CNY 140,865,673.22 in Q1 2022[48]. - Net profit for Q1 2023 was CNY 8,844,695.02, down from CNY 61,838,295.13 in Q1 2022, representing a decline of 85.7%[40]. - Adjusted net profit margin decreased to 34.29%, down 8.98 percentage points from the previous year[33]. - The company reported a total comprehensive income of CNY 8,676,508.73 for Q1 2023, significantly lower than CNY 61,781,840.32 in Q1 2022[41]. - The company recorded a net profit of CNY 13,610,162.34, a significant decrease from CNY 70,319,504.08 in the previous period[49]. Cash Flow and Assets - The net cash flow from operating activities was a negative CNY 2,477.53 million, primarily due to significant tax payments and employee performance bonuses in Q1[9]. - Cash inflow from operating activities in Q1 2023 was CNY 163,256,853.71, an increase from CNY 106,440,903.89 in Q1 2022[42]. - Total assets increased to CNY 2,026,598,984.12 in Q1 2023 from CNY 1,952,900,334.44 in Q1 2022, marking a growth of 3.8%[40]. - Cash and cash equivalents at the end of the period totaled CNY 377,117,428.47, up from CNY 212,473,150.26[53]. - The company’s cash and cash equivalents decreased to CNY 10,993,679.20 in Q1 2023 from CNY 14,428,250.40 in Q1 2022, a decline of 23.8%[40]. - The total liabilities decreased to CNY 1,088,818,555.81 in Q1 2023 from CNY 1,143,544,138.66 in Q1 2022, a decrease of 4.8%[40]. Research and Development - R&D investment totaled CNY 3,808.96 million, an increase of 136.89% year-on-year, representing 28.83% of operating revenue, up 17.42 percentage points[4]. - Research and development expenses reached CNY 38,089,598.74, significantly up from CNY 16,078,773.37, indicating a focus on innovation[49]. - The company launched new products including UniGel-65Q HC and STS0100 oligonucleotide synthesizer during the reporting period[9]. Shareholder Information - The total number of common shareholders at the end of the reporting period was 15,044[28]. - Major shareholder Shenzhen Nawei Technology Co., Ltd. holds 19.37% of the shares, totaling 78,096,992 shares[28]. - Equity attributable to shareholders of the listed company was CNY 159,270.72 million, reflecting a growth of 3.01% year-over-year[25]. Government Support and Other Income - The company received government subsidies amounting to CNY 385.86 million, which are closely related to its normal operations[25]. - The company reported a total of CNY 637.20 million in other income and expenses after tax impacts and minority interests[25]. - The total income from other sources was CNY 3,843,963.12, compared to CNY 2,383,320.11 previously, reflecting improved performance in ancillary revenue streams[49].